A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Inclusion until disease progression
No
Lynne Bui, MD
Study Director
Exelixis, Inc.
United States: Food and Drug Administration
XL999-206
NCT00277303
December 2005
February 2007
Name | Location |
---|---|
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
California Cancer Care, Inc. | Greenbrae, California 94904-2007 |
University of Chicago | Chicago, Illinois 60637 |
Center for Oncology Research and Treatment, PA | Dallas, Texas 75230 |
Hematology Oncology Associates of Rockland, PC | New York City, New York 10956 |
Integrated Community Oncology Network; Division of Clinical Research | Jacksonville, Florida 32256 |
Hematology Oncology Associated of the Treasure Coast | Port St. Lucie, Florida 34952 |
Joliet Oncology-Hematology Associated, Ltd. | Joliet, Illinois 60435 |